Press Releases

Dr. Quarraisha Abdool Karim, Hideyo Noguchi Africa Prize Winner, Joins GHIT Fund Board of Directors

Approximately USD 10.8 Million Invested in New Drug Development for Malaria and NTDs in Partners including Japanese pharma Shionogi, Mitsubishi Tanabe, and Eisai and Europe-based institutions

EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children
GHIT has financed the Pediatric Praziquantel Consortium’s development of arpraziquantel since 2013, investing 1.85 billion yen

Investment of Approximately USD 8.8 Million for New Drug Development against Malaria in Partners including Marubeni and Eisai

GHIT Fund Welcomes EIKEN CHEMICAL as New Sponsor

GHIT Fund and the Medicines Patent Pool Strengthen Ties to Improve Access to Medicines

Global Health Innovative Technology Fund and Institut Pasteur de Dakar Announce New Partnership to Advance Research and Development for New Diagnostics and Vaccines in LMICs

Approximately USD 8 million Investment for New Vaccine and Drug Development against Malaria in Sumitomo Pharma, Mitsubishi Tanabe Pharma and new product development in NTDs

GHIT Fund Welcomes Remedy & Company Corporation as New Funding Partner

GHIT Fund welcomes Fujirebio as New Funding Partner

Global health leaders adopt the Nagasaki Outcomes Statement and jointly call for the acceleration of R&D, access, and delivery for neglected tropical diseases

Government of Japan Express its Pledge of US$200 Million to GHIT Fund/UNDP Replenishment

“Nagasaki Outcome Statement” to accelerate progress on neglected tropical diseases (NTDs) for G7 Health Ministers. “Accelerating Research and Development, and Access and Delivery for NTDs”

GHIT Fund Secures USD 24 million pledge from Bill & Melinda Gates Foundation over 3 years

A Total of Approximately 400 Million Yen Investment in Eisai, Ehime University, DNDi and Others for New Drug and Vaccine Development for Neglected Tropical Diseases

GHIT Fund Announces New Investments: A Total of Approximately 260 Million Yen in Shionogi, Takeda Pharmaceutical for New Malaria Drug Development

Unitaid and the Global Health Innovative Technology Fund strengthen ties to improve access to critical health tools

The European Medicines Agency (EMA) Validated Regulatory Application for Arpraziquantel, a potential Treatment for Schistosomiasis in Preschool-Aged Children

GHIT Fund Secures US$20 million pledge from Wellcome over 5 years

GHIT Fund Announces New Investments: A Total of 790 Million Yen for Product Development of Neglected Tropical Diseases

CEPI and GHIT collaborate to advance the global fight against infectious diseases

GHIT Fund Announces New Investments: A Total of 740 Million Yen for Malaria Drugs and Vaccine

GHIT Fund Announces Appointment of Dr. Osamu Kunii as New CEO

The Pediatric Praziquantel Consortium Announces Positive Phase III Results for Arpraziquantel To Treat Schistosomiasis

GHIT Fund Announces New Investments: A Total of 750 Million Yen in Drugs for Malaria and Chagas Disease, Vaccine for Malaria, and Diagnostics for Tuberculosis

GHIT Fund Announces New Investment: 97.4 Million Yen to Identify Novel Dual-Acting Bactericidal Drug Targets Against Mycobacterium Tuberculosis

GHIT Fund Announces New Investments: A Total of 960 Million Yen in Drugs for Leishmaniasis and Diagnostics for Buruli Ulcer and Chagas Disease

GHIT Fund Announces New Investments: A Total of 2.3 Billion Yen in Drugs for Malaria, Tuberculosis, Chagas Disease and Visceral Leishmaniasis, Vaccine for Malaria and Diagnostics for Tuberculosis

GHIT and EDCTP co-invest additional 7.8 million Euro in the Pediatric Praziquantel Consortium's access program to ensure treatment of schistosomiasis for preschool-aged children

GHIT Fund Announces New Investments: A Total of 230 Million Yen in Drugs for Malaria and Chagas Disease

GHIT Fund Announces New Investments: A Total of 1.37 Billion Yen in Drugs for Malaria, Chagas Disease, Leishmaniasis, Schistosomiasis, and Soil-Transmitted Helminths, and Diagnostics for Malaria, Buruli Ulcer, and Schistosomiasis

GHIT Fund Announces New Investments: A Total of 3.29 Billion Yen in Drugs for Malaria, Tuberculosis, Chagas Disease, Lymphatic Filariasis, and Onchocerciasis, Vaccines for Malaria, and Diagnostics for Leishmaniasis and Mycetoma

Statement: The Global Health Innovative Technology Fund and Unitaid collaboration to accelerate access to innovative solutions

GHIT Fund Announces New Investments: A Total of 630 Million Yen in Drug for Malaria, Tuberculosis, Chagas disease, and Leishmaniasis, Vaccines for Malaria and Chagas disease, and Diagnostics for Malaria

GHIT Fund Announces Appointment of Catherine Ohura as New CEO and Executive Director

GHIT Fund Announces New Investments: A Total of 2.86 Billion Yen in Drug for Schistosomiasis, Dengue, Malaria and Tuberculosis, Vaccines for Leishmaniasis and Malaria, and Diagnostics for Tuberculosis

GHIT Fund Announces New Investments in Vaccines for Dengue and Leishmaniasis, and Drug Screening for Malaria and Tuberculosis

GHIT Fund welcomes Ono Pharmaceutical Co., Ltd. as New Funding Partner

GHIT Fund Invests in FIND and Fujifilm for Development of Innovative Rapid Diagnostic Tool for Tuberculosis

GHIT Fund Names Hiroki Nakatani as Board Chair

As the GHIT Fund Closes Out First Five Years of R&D for Lifesaving Medical Breakthroughs, It Launches Next Phase, Focusing on Access and Delivery, Bringing Total Investment to 13.2 Billion Yen (US$123 Million)

GHIT Fund’s Strategic Plan for 2018 to 2022: Accelerating Product Development and Product Delivery for its global health innovations

EDCTP and Global Health Innovative Technology Fund partnership for the development of a paediatric formulation for schistosomiasis

GHIT Fund Accelerates Promising Efforts to Find New Treatments, Vaccines and Diagnostics for Malaria, Tuberculosis, Leishmaniasis and Mycetoma

GHIT Fund Secures Commitments of Over US$200 Million to its Replenishment for the Acceleration of Japanese Innovation for Infectious Diseases of the Developing World

GHIT Fund Invests in Late-stage Trial for Child-friendly “Snail Fever” Medicines—One of the Most Debilitating and Widespread Parasitic Diseases in Africa

GHIT Fund Steps Up Battle Against Neglected Diseases With Continued Investments to Move Promising Research Through the Pipeline

GHIT Fund Welcomes Ten New Partnerships With FUJIFILM, Otsuka, GSK, Johnson & Johnson, Kyowa Hakko Kirin, Merck, Mitsubishi Tanabe, Nipro, Sumitomo Dainippon Pharma and Salesforce.com

Government of Japan Announces Decision to Contribute US$130 million to GHIT Fund/UNDP Replenishment

GHIT Fund Announces New Investments, Including Innovative Malaria Vaccine Targeting Two Deadliest Strains of the Disease

From a Phase 2 TB Vaccine Trial, to Early Work to Neutralize Drug-Resistant Malaria, $10.7 Million in New Investments from GHIT Fund Escalates and Diversifies Japan’s Global Health Commitments

GHIT, Takeda and MMV progress first-in-class antimalarial DSM265 to patient trials in Peruvian Amazon

GHIT Fund Welcomes the Wellcome Trust and Sysmex Corporation as New Funders and ANA, Morrison & Foerster, and Yahoo! Japan as New Sponsors

DNDi and Four Pharmaceutical Companies Announce ‘Drug Discovery Booster’ Experiment to Accelerate and Expand Discovery of New Drugs for Two Highly Neglected Diseases – Leishmaniasis and Chagas disease

GHIT Fund Expands Portfolio to Nearly $43 Million with Inclusion of First Diagnostic Technology, New Drug Series for Leishmaniasis, and Four New Companies to its Screening Platform

New Investment in Promising Compounds for Antimalarial Drug Discovery

GHIT Fund Launches Target Research Platform in partnership with Grand Challenges

Chugai Pharmaceutical Joins GHIT Fund as Partner, Further Expanding Japanese Innovation to Target Diseases that Affects the World’s Poorest People

Call for greater collaboration between East and West to tackle inevitable threat of infectious diseases

GHIT Fund Awards $60,000 Grant Investment to Develop Innovative New Malaria Treatment

Seven New Grant Investments for $15.3 Million to Tackle Malaria, Chagas Disease and Dengue, which is Dramatically on the Rise

GHIT Certified As A Public Interest Incorporated Association

With a Pledge for New Funding, Global Health Innovative Technology Fund Endorses London Declaration on Neglected Tropical Diseases

Japanese Fund Moves Quickly to Invest in Promising Technology Against Malaria, Tuberculosis And Chagas Disease

Japan Launches Bold Effort to Fight Neglected Diseases by Screening Massive Drug Compound “Libraries” for New Treatments

Announcement of the Establishment of The Global Health Innovative Technology Fund